OXIGENE INC
4/A, 1999-10-13
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: OXIGENE INC, 4, 1999-10-13
Next: USAA FEDERAL SAVINGS BANK, 8-K, 1999-10-13





<TABLE>
- -------------------------               UNITED STATES SECURITIES AND EXCHANGE COMMISSION              ------------------------------
         FORM 4                                      Washington, D.C. 20549                                     OMB Approval
- -------------------------                 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP                ------------------------------
[ ] Check this box if no                                                                               OMB Number:        3235-0287
    longer subject to        Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,   Expires:  September 30, 1998
    Section 16. Form 4         Section 17(a) of the Public Utility Holding Company Act of 1935 or      Estimated average burden
    or Form 5 obligations              Section 30(f) of the Investment Company Act of 1940             hours per response.......0.5
    may continue. See                                                                                 ------------------------------
    Instruction 1(b).

<CAPTION>
    (Print or Type Responses)
<S>                                         <C>                            <C>               <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1.  Name and Address of Reporting Person*   2. Issuer Name and Ticker      4. Statement for  6. Relationship of Reporting Person(s)
                                               or Trading Symbol              Month/Year        to Issuer
                                                                                                      (Check all applicable)
    HAGLUND, BO                                OXiGENE Inc. (OXGN)            9/1999         [ ] Director        [ ] 10% Owner
    ------------------------------------                                                     [X] Officer (give   [ ] Other
    (Last)        (First)      (Middle)                                                          title below)        (specify below)

    c/o OXiGENE, Inc.                                                                        Chief Financial Officer
    One Copley Place, Suite 602                                                              ---------------------------------------
    ------------------------------------   -----------------------------------------------------------------------------------------
                  (Street)                  3. I.R.S. Identification       5. If Amendment,  7. Individual or Joint/Group Filing
                                               Number of Reporting            Date of               (Check Applicable Line)
                                               Person, if an entity           Original       [X] Form Filed by One Reporting Person
    Boston, MA 02116                           (Voluntary)                    (Month/Year)   [ ] Form Filed by More than One
    ------------------------------------                                                         Reporting Person
    (City)        (State)        (Zip)                                        10/12/99

- ------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
                       TABLE I -- NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
<S>                       <C>         <C>              <C>                          <C>               <C>             <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Security      2. Trans-   3. Transaction    4. Securities Acquired (A)  5. Amount of      6. Ownership    7. Nature of
   (Instr. 3)                action      Code (Instr.      or Disposed of (D)          Securities        Form:           Indirect
                             Date        8)                (Instr. 3, 4 and 5)         Beneficially      Direct (D)      Beneficial
                             (Month/                                                   Owned at End      or Indirect     Ownership
                             Day/                                                      of Month          (I)             (Instr. 4)
                             Year)                                                     (Instr. 3         (Instr. 4)
                                                                                       and 4)
- ------------------------------------------------------------------------------------------------------------------------------------
                                         Code     V     Amount  (A) or (D)  Price
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock              09/01/99        A             24,253       A      $8.9375                       D
- ------------------------------------------------------------------------------------------------------------------------------------
                          09/01/99        A             10,000       A      $8.3130    34,253             D
- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------
Reminder:  Report on a separate line for each class of securities beneficially owned directly or indirectly.
*  If the form is filed by more than one reporting person, see Instruction 4(b)(v).

                                                                                                                         Page 1 of 2
</TABLE>

<PAGE>

<TABLE>
FORM 4 (continued)

<CAPTION>
         TABLE II -- DERIVATIVE SECURITIES BENEFICIALLY OWNED (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
<S>       <C>         <C>        <C>       <C>            <C>           <C>           <C>      <C>        <C>         <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title  2. Conver-  3. Trans-  4. Trans- 5. Number of   6. Date       7. Title      8. Price 9. Number  10. Owner-  11. Nature of
   of        sion or     action     action    Derivative     Exer-         and           of       of          ship        Indirect
   Deri-     Exercise    Date       Code      Securities     cisable       Amount        Deri-    Deri-       Form        Beneficial
   vative    Price of               (Instr.   Acquired (A)   and Expi-     of            vative   vative      of Deri-    Ownership
   Secu-     Deri-       (Month/    8)        or Disposed    ration        Under-        Secu-    Secu-       vative      (Instr. 4)
   rity      vative      Day/                 of (D)         Date          lying         rity     rities      Security:
   (Instr.   Security    Year)                (Instr. 3,     (Month/       Securi-       (Instr.  Benefi-     Direct
   3)                                         4, and 5)      Day/          ties          5)       cially      (D) or
                                                             Year)         (Instr.                Owned       Indirect
                                                                           3 and 4)               at End      (I)
                                                                                                  of          (Instr.
                                                                                                  Month        4)
                                                                                                  (Instr.
                                                                                                  4)
- ------------------------------------------------------------------------------------------------------------------------------------
                                    Code V    (A)   (D)    Date    Expir- Title Amount
                                                           Exerci- ation        or
                                                           sable   Date         Number
                                                                                of
                                                                                Shares
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock  $8.9375   9/1/99      A                      Immed.  9/1/09 Common  24,253            24,253     D
Option                                                                    Stock
(right to
purchase)(1)
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock  $8.3130   9/1/99      A                      Immed.  9/1/09 Common  10,000            10,000     D
Option                                                                    Stock
(right to
purchase)(1)
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock  $8.9375   9/1/99      D                      Immed.  9/1/09 Common  24,253                 0
Option                                                                    Stock
(right to
purchase)(1)
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock  $8.3130   9/1/99      D                      Immed.  9/1/09 Common  10,000                 0
Option                                                                    Stock
(right to
purchase)(1)
- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

Explanation of Responses:

(1) The Common Stock Options were issued pursuant to the OXiGENE 1996 Stock Incentive Plan, as amended, and  in accordance with the
    laws of Sweden, were immediately exercisable upon the date of grant, subject to a right of repurchase by OXiGENE. The reporting
    person exercised the Common Stock Options on 9/1/99 by executing a promissory note in the amount of the aggregate exercise
    price, payable to OXiGENE and secured by the shares of Common Stock purchased by the reporting person.


** Intentional misstatements or omissions of
   facts constitute Federal Criminal Violations.
   See 18 U.S.C. and 15 U.S.C. 78ff(a).              By: /S/  BO HAGLUND                                       October 12, 1999
                                                         -------------------------------------             -------------------------
                                                         Bo Haglund                                                 Date
Note:    File three copies of this Form, one of
         which must be manually signed. If space
         is insufficient, see Instruction 6 for
         procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless form
displays a currently valid OMB number.

                                                                                                                         Page 2 of 2
</TABLE>




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission